Gamma knife surgery for cavernous sinus hemanginoma: a report of 32 cases

Background Cavernous sinus hemangioma (CSH) is a rare type of benign vascular tumor. Microsurgery for CSH treatment usually results in profuse bleeding and cranial nerve injury. Radiosurgery is an alternative treatment for CSH. The objective of this study was to elucidate the efficacy and safety of...

Full description

Saved in:
Bibliographic Details
Published in:World neurosurgery 2016-10, Vol.94, p.18-25
Main Authors: Wang, Yi, M.D, Li, Peng, M.D, Zhang, Xin J., M.D, Xu, Yang Y., M.D, Wang, Wei, M.D
Format: Article
Language:English
Subjects:
Adult
Aged
Brain Neoplasms - diagnostic imaging
Brain Neoplasms - pathology
Brain Neoplasms - radiotherapy
Cavernous Sinus
Cavernous sinus hemangioma
Female
Gamma knife
Hemangioma - diagnostic imaging
Hemangioma - pathology
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Neurosurgery
Radiosurgery - methods
Stereotactic radiosurgery
Treatment Outcome
Tumor Burden
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Cavernous sinus hemangioma (CSH) is a rare type of benign vascular tumor. Microsurgery for CSH treatment usually results in profuse bleeding and cranial nerve injury. Radiosurgery is an alternative treatment for CSH. The objective of this study was to elucidate the efficacy and safety of gamma knife surgery (GKS) for the treatment of CSH. Methods 32 patients with CSH underwent 34 times of GKS as a primary and exclusive treatment from 2009 to 2015 at West China Hospital. The diagnosis was mainly based on findings of magnetic resonance imaging (MRI). The treatment was performed with the Leksell Gamma Knife model C. The follow-up period was from 12 to 67 months. Changes in imaging results and signs or symptoms were analyzed. Studies of patients undergone radiosurgery and microsurgery were compared. Results Clinical improvement was observed after GKS in 26 of 27 patients presented with signs or symptoms of CSH. Tumor shrinkage was detected in all cases. A reduction in tumor volume of 0 to 25%, 26 to 50%, 51 to 75%, and 76 to 100% was observed in 3, 2, 8, and 19 cases, respectively. Remarkable tumor shrinkage occurred within 6 to 12 months after GKS. According to a retrospective analysis of 151 patients diagnosed with CSH, 77 patients underwent GKS without any complications, 17 of 74 patients treated with microsurgery exhibited persistent complications, and 1 patient died. Conclusion GKS is a safe and effective treatment for most cases of CSH. The concept of GKS as an adjuvant treatment for CSH requires reconsideration.
ISSN:1878-8750
1878-8769
DOI:10.1016/j.wneu.2016.06.094